{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-262976","form_type":"8-K/A","ticker":"XAGE","cik":"0001842939","company_name":"Longevity Health Holdings, Inc.","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.971468+00:00","generated_at":"2026-06-09T11:37:23.816419+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Carmell Corp files Axolotl Biologix H1 2023 financials: rev $21.9M, NI $1.8M","bullets":["Axolotl H1 2023 revenue $21.9M (up 56% YoY from $14.0M) and net income $1.8M (up 57% from $1.2M).","Single customer (Customer A) and single product (Dualgraft) represent 100% of revenue.","Cash and equivalents $698k; accounts receivable $17.2M; inventory $2.6M.","Related-party loans from Burns Ventures $5.6M noncurrent; inventory purchases from Pinnacle $2.5M in H1 2023.","Operating cash flow negative $701k; cash decreased from $1.4M to $698k in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-262976","json":"https://secwatch.observer/filing/0001193125-23-262976.json","markdown":"https://secwatch.observer/filing/0001193125-23-262976.md","text":"https://secwatch.observer/filing/0001193125-23-262976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523262976/0001193125-23-262976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842939/000119312523262976/d568161d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:37:23.816419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}